- \n
- Q1 2019 Group sales growth of 17.0% as reported, or 15.8%1<\/sup>\u00a0at constant exchange rates and consolidation scope driven by:\n
- \n
- Specialty Care sales growth of 17.6%1<\/sup>, with continued strong momentum across all major products and geographies<\/li>\n
- Consumer Healthcare sales growth of 3.3%1<\/sup><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
- \n
- Full Year 2019 guidance confirmed following the completion of the acquisition of Clementia Pharmaceuticals on 17 April:\n
- \n
- Group sales growth greater than 13.0%1<\/sup>\u00a0at constant exchange rates and consolidation scope. Based on the current level of exchange rates, there is an expected +2.0% impact from currencies.<\/li>\n
- Core Operating Income margin around 30.0% of net sales (excluding incremental investments in pipeline expansion initiatives)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
First quarter 2019 unaudited IFRS consolidated sales <\/p>\n
\n
\n (in\u00a0million euros)<\/em> <\/td>\n Q1 2019<\/strong> <\/td>\n Q1 2018<\/strong> <\/td>\n % <\/em>
Change<\/em> <\/td>\n% Change
at constant currency & consolidation scope1<\/sup><\/em> <\/td>\n<\/tr>\n\n \u00a0<\/strong> <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Specialty Care <\/td>\n 530.9 <\/td>\n 440.4 <\/td>\n +20.5%<\/em> <\/td>\n +17.6%<\/em> <\/td>\n<\/tr>\n \n Consumer Healthcare <\/td>\n 66.3 <\/td>\n 69.9 <\/td>\n -5.2%<\/em> <\/td>\n +3.3%<\/em> <\/td>\n<\/tr>\n \n Group Sales<\/strong> <\/td>\n 597.2<\/strong> <\/td>\n 510.3<\/strong> <\/td>\n +17.0%<\/em><\/strong> <\/td>\n +15.8%<\/em><\/strong> <\/td>\n<\/tr>\n<\/table>\n \u00a0<\/p>\n
David Meek, Chief Executive Officer<\/strong>\u00a0of Ipsen<\/strong>\u00a0stated: \u201cWith robust double-digit sales growth in the first quarter, Ipsen is on track for another year of outstanding business execution. The Specialty Care business continues to thrive across all major products and geographies with volume and market share gains. We are accelerating the ongoing transformation of Ipsen by executing on our external innovation strategy to strengthen the R&D pipeline with novel first and best-in-class assets.<\/em>
\u201cNotably, in the first quarter, we announced and completed the acquisition of Clementia Pharmaceuticals, a company focused on the treatment of rare and severely-disabling bone disorders. Palovarotene is a largely de-risked near-term launch opportunity with significant upside potential. Together, with our new colleagues from Clementia, we will leverage our combined scientific and development expertise to deliver new treatments to patients with high unmet medical needs.<\/em>\u201d<\/p>\nConference call<\/u><\/strong><\/p>\n
Ipsen will host a conference call on Wednesday 24 April 2019 at 2:30 p.m. (Paris time, GMT+1). A conference call will take place and a web conference (audio and slides) will be available at\u00a0www.ipsen.com<\/strong><\/a>. Participants should dial in to the call approximately 5 to 10 minutes prior to its start. No reservation is required to participate in the conference call.
Standard International: +44 (0) 2071-928-000
France and continental Europe: + 33 (0) 1 76 70 07 94
UK: 08-445-718-892
U.S.: 1-6315-107-495
Conference ID: 9846139
A recording will be available for 7 days on Ipsen\u2019s website.<\/p>\n\u2014<\/p>\n
- Core Operating Income margin around 30.0% of net sales (excluding incremental investments in pipeline expansion initiatives)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
- Group sales growth greater than 13.0%1<\/sup>\u00a0at constant exchange rates and consolidation scope. Based on the current level of exchange rates, there is an expected +2.0% impact from currencies.<\/li>\n
- Consumer Healthcare sales growth of 3.3%1<\/sup><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
- Specialty Care sales growth of 17.6%1<\/sup>, with continued strong momentum across all major products and geographies<\/li>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-3690","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"\n